The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 330008, China
NCT Number: NCT06796283
The purpose of this observational study is to construct a recurrence risk prediction model for ischemic stroke within 1, 3, 6, and 12 months using XGBoost combined with Convolutional Neural Network (CNN) algorithm.
Method: Follow up was conducted on the study subjects at 1, 3, 6, and 12 months after discharge.
Follow up primary outcome: Whether the study subjects experienced recurrent stroke events.
Secondary outcome: Improved Rinkin score.
Collect information on research subjects:
It includes demographic data, physical examination, medical history, imaging images, medication use, scale scores, CYP2C19 genotype test results, laboratory tests, and other complex multidimensional data.
Looking for future studies?
Notify Me18 year–85 year
All sexes
Observational
Nanchang, Jiangxi, 330008, China
This project conducts a one-year follow-up on the enrolled subjects (patients with ischemic stroke) to observe the recurrence and modified Rankin scores after discharge. Combining complex multidimensional data such as demographic information, physical examination, medical history, imaging images, medication status, NIHSS scale scores, Glasgow Coma Scale scores, CYP2C19 genotype test results, and laboratory examinations of the subjects; Convolutional Neural Networks (CNNs) are used to segment lesions and extract features from the subjects' imaging images; Cox regression models are employed to obtain factors influencing recurrence; a prediction model for the risk of recurrence within 1, 3, 6, and 12 months for ischemic stroke is constructed using the XGBoost algorithm combined with Convolutional Neural Networks. The exploration aims to provide new insights and methods for the prevention and control of major chronic diseases by evaluating the effectiveness of XGBoost in predicting the risk of ischemic stroke recurrence at different times.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: April 6th, 2021- March 12th, 2024
Follow up was conducted on the study subjects at 1, 3, 6, and 12 months after discharge, with the main outcome being whether the study subjects experienced stroke recurrence events
Time frame: April 6th, 2021- March 12th, 2024
Follow up was conducted on the study subjects at 1, 3, 6, and 12 months after discharge, with the secondary outcome being the modified Rinkin score.Improved Rinkin Scale:
Completely asymptomatic (0 points). Despite symptoms, there is no obvious functional impairment and the ability to complete all daily work and life tasks (1 point).
Mild disability, unable to complete all pre illness activities, but able to take care of daily affairs without assistance (2 points).
Moderate disability, requiring partial assistance, but able to walk independently (3 points).
Moderate to severe disability, unable to walk independently, requiring assistance from others in daily life (4 points).
Severe disability, bedridden, urinary incontinence, and complete dependence on others in daily life (5 points).
The higher the score, the worse the participant's neurological function recovery.
Second Affiliated Hospital of Nanchang University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05416853
Arterial Occlusive Diseases, Brain Diseases
Hefei, Anhui, China
View Trial DetailsNCT07709806
Brain Diseases, Cardiovascular Diseases
Siping, Jilin, China
View Trial DetailsNCT07654582
Brain Diseases, Cardiovascular Diseases
Cairo, Egypt
View Trial DetailsNCT06049498
Brain Diseases, Cardiovascular Diseases
Beijing, China
View Trial Details